Atlas Trials

Observational Study on the Long Term Safety of Kuvan® Treatment in Patients With Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or BH4 Deficiency

Clinical trial NCT01016392 · COMPLETED

Trial details

NCT number
NCT01016392
Sponsor
BioMarin Pharmaceutical
Status
COMPLETED
Study type
OBSERVATIONAL
Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or Tetrahydrobiopterin (BH4) Deficiency
Start date
2009-12-01
Primary completion
2021-05-31
Enrollment
627

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.